An observational study in Postoperative Pneumonia and Brain Tumors, sponsored by Ming Yang. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Ming Yang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies in Brain Neoplasms with a site in China — 73 open to participants now, 84 under way, 7 of them phase 3. Brain Neoplasms · China.
Among the 180 studies in Brain Neoplasms with a site in China, this one is the 9th largest by enrollment of the 37 observational ones that give a count, is one of 17 that started in 2024, is one of 37 observational ones, and was the 160th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →73 of the 180 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:
Beijing Inno Medicine Co., Ltd. · Sites in China, United States
Ages 18–70
Bristol-Myers Squibb · Sites in China, United States, Belgium and 10 more countries
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18–70
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 76 · Phase 3 23 · Phase 4 3
First in 1997; this study’s year is marked. 17 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,856 is above the median of 99 across 433 observational studies indexed under Brain Neoplasms.
Median enrollment 60 across the 143 interventional studies, 358 across the 37 observational. Of the 41 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 180 have an industry lead sponsor. The 10 most frequent:
Ming Yang is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Ming Yang has 2 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Brain Neoplasms with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT06457906Phase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesSRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC | 2027-08-30 |
| NCT07446842Tongji HospitalConstruction of AI Model for Precision Imaging Diagnosis of Cranial Diseases | 2026-12 |
| NCT06231186Ruijin Hospitala Feasibility Study of iHD-SRT for BM | 2026-12 |
| NCT06793332Fudan UniversityBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 180 studies in Brain Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postoperative pneumonia (POP) is a common and serious complication after elective craniotomy for brain tumor resection. POP often develops within the first week after surgery and may lead to prolonged hospitalization, higher medical costs, and increased risk of severe illness. Because symptoms can be subtle in neurosurgical patients, POP may be detected late, limiting timely prevention and treatment.
This study will evaluate whether a machine-learning-based clinical decision support tool can help clinicians identify patients at high risk for POP early and improve perioperative preventive care. The tool uses routinely collected clinical information to estimate an individual patient's POP risk and provides an easy-to-understand explanation of key risk drivers. Based on the predicted risk level (low, moderate, high, or very high), the system suggests standardized preventive care pathways (e.g., perioperative airway management, targeted antibiotic strategies per local practice, and nutritional support), while allowing clinicians to override recommendations at any time.
Participants will be adults undergoing their first elective craniotomy for brain tumor resection at participating neurosurgical centers. The primary outcome is the occurrence of POP within 7 days after surgery, defined using CDC/NHSN criteria. Secondary outcomes include antibiotic use intensity, length of hospital stay, direct medical cost, and clinician decision confidence. Participants will be followed at postoperative days 1, 3, and 7 using electronic medical record review and phone confirmation when needed.
The goal of this study is to determine whether integrating an explainable AI risk prediction tool into routine care can reduce POP and improve the quality and efficiency of perioperative management after brain tumor surgery.
Rationale Postoperative pneumonia (POP) remains a frequent and clinically important complication after elective craniotomy for brain tumor resection, contributing to prolonged hospitalization, increased cost, and worse clinical outcomes. Conventional POP risk assessment is often experience-based or relies on simplified scoring approaches, which may not adequately capture nonlinear interactions among perioperative factors. This study implements an explainable machine-learning (ML) prediction model within routine perioperative workflows and evaluates whether model-assisted care can improve POP prevention and related resource utilization compared with usual care.
Decision support system
An explainable gradient boosting machine (GBM) model is used to estimate individual POP risk from routinely available perioperative variables. Interpretability is provided using SHAP-based explanations at two complementary levels:
Population level: summarizes the most influential predictors and selected interaction patterns to support clinical understanding and model governance.
Patient level: generates an individualized contribution visualization (e.g., waterfall-style), highlighting the main drivers of a specific patient's risk estimate.
The system automatically assigns a risk tier (low, moderate, high, or very high) and links each tier to standardized prevention pathway templates (e.g., airway management optimization, antimicrobial stewardship-consistent strategies per local policy, and nutritional support). The tool does not mandate treatment; clinicians may accept, modify, or override any suggestion.
Evaluation framework The overall project includes retrospective model development/optimization, prospective external validation/calibration, and a pragmatic implementation evaluation. The registered interventional evaluation uses a multicenter, cluster randomized crossover design with monthly alternating periods of model-assisted care versus usual care. Allocation procedures, eligibility criteria, planned enrollment, and endpoint definitions/time windows are specified in the corresponding record modules (Study Design, Arms/Interventions, Outcome Measures, and Eligibility) to avoid duplication in this section.
Implementation and integration The model is deployed as a lightweight web service with unified APIs and data-exchange formats to enable non-disruptive integration with hospital information systems (HIS) and electronic medical records (EMR). A web-based front end and a Python-based back end support RESTful calls and are designed for low-latency inference (target single-prediction latency \<200 ms), suitable for perioperative and inpatient workflows.
Data governance and model updating To support long-term generalizability across hospitals and mitigate dataset shift, the project establishes a closed-loop maintenance process ("local de-identification → cloud retraining → model version management → edge deployment"). Model updates are version-controlled and deployed under governance procedures consistent with local regulations, institutional policies, and applicable ethics approvals.
Adult patients undergoing elective craniotomy for intracranial brain tumor resection at participating centers. The study includes a retrospective model-development cohort and multiple prospective validation cohorts. Routinely collected perioperative electronic medical record data are used to develop and validate an interpretable prediction model for early postoperative pneumonia (within 7 postoperative days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Retrospective cohort collected at the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS/PUMC) between Jan 1, 2022 and Oct 31, 2024. Adult patients undergoing elective craniotomy for intracranial brain tumor resection were included. This cohort was used for model development, comparison of candidate algorithms, and internal validation; it was randomly split 8:2 into a training set (n=609) and an internal validation set (n=152). Early postoperative pneumonia (POP) was defined by CDC criteria within 7 days postoperatively. No study-mandated intervention was applied; routine perioperative care was provided.
Prospective cohort enrolled at CAMS/PUMC between Nov 1, 2024 and Apr 30, 2025 (Test P; n=224). Adult patients undergoing elective craniotomy for brain tumor resection were included. This cohort prospectively validated the finalized interpretable prediction model for early POP using routinely available perioperative EMR variables. Early POP was defined per CDC criteria within 7 postoperative days. Clinical management followed standard-of-care without any study-assigned intervention.
Prospective external validation cohort recruited at the First Affiliated Hospital of Anhui Medical University from Aug 1, 2024 to Apr 30, 2025 (Test A; n=329). Adult patients undergoing elective craniotomy for brain tumor resection were included. The cohort independently validated the finalized POP prediction model using routine perioperative data. Early POP was defined by CDC criteria within 7 days after surgery. No investigational intervention was administered; all care followed local standard practice.
Prospective external validation cohort recruited at Shandong Cancer Hospital from Aug 1, 2024 to Apr 30, 2025 (Test S; n=440). Adult patients undergoing elective craniotomy for intracranial brain tumor resection were included. This cohort was used to externally validate the finalized interpretable model for early POP prediction using routinely collected perioperative variables. Early POP was defined according to CDC criteria within 7 postoperative days. Participants received routine perioperative management per institutional standards without study-mandated interventions.
Prospective external validation cohort recruited at Jinan Fourth People's Hospital from Aug 1, 2024 to Apr 30, 2025 (Test J; n=102). Adult patients undergoing elective craniotomy for brain tumor resection were included. The cohort externally validated the finalized prediction model for early POP based on routine perioperative EMR data. Early POP was defined per CDC criteria within 7 postoperative days. There was no study-assigned intervention; all patients received standard perioperative care per local protocols.
Incidence of early postoperative pneumonia (POP)
Early POP was diagnosed according to CDC criteria and recorded in the electronic medical record, assessed as a binary outcome (POP vs no POP) within 7 postoperative days.
Time frame: Within 7 days after craniotomy (postoperative day 0-7)
Discrimination of the finalized prediction model (AUC)
Area under the receiver operating characteristic curve (AUC) for the finalized interpretable logistic regression model in predicting early POP (binary outcome within 7 days).
Time frame: Within 7 days after craniotomy (postoperative day 0-7)
Calibration performance of the finalized prediction model
Calibration assessed using calibration curve and summary statistics (e.g., calibration intercept and slope; Brier score), comparing predicted probabilities with observed early POP outcomes.
Time frame: Within 7 days after craniotomy (postoperative day 0-7)
Clinical utility of the finalized prediction model (Decision Curve Analysis)
Net benefit of the finalized model evaluated by decision curve analysis across clinically relevant threshold probabilities for early POP.
Time frame: Within 7 days after craniotomy (postoperative day 0-7)
Classification performance of the finalized prediction model at a pre-specified cutoff
Sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), and F1 score calculated at a pre-specified probability threshold (e.g., determined in the training cohort using Youden index) and applied to validation cohorts.
Time frame: Within 7 days after craniotomy (postoperative day 0-7)
Plan to share: Undecided — IPD sharing is currently undecided. The study uses detailed multi-center electronic medical record data, and additional assessment is needed to determine whether an adequately de-identified dataset can be shared without meaningful risk of re-identification and in compliance with IRB/ethics approvals, institutional policies, and applicable privacy regulations. We will revisit the IPD sharing plan after study completion and publication of primary results.
Ran from Aug 2024 to primary completion in Apr 2025, 8 months.
Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's 8 months is below that.
Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ming Yang